DSDhruva Sharma

Dhruva Sharma

*This is an algorithmically generated author record based on publicly available information.

Dhruva Sharma has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non-hypertension-associated Posterior Reversible Encephalopathy Syndrome in COVID-19

    by Dhruva Sharma, Sachin Gupta, Deeksha S Tomar

    Background: Coronavirus disease-2019 (COVID-19) infection-related neurological events are not uncommon but presenting as posterior reversible encephalopathy syndrome (PRES) without hypertension is a very rare presentation and requires a high index of suspicion. Case summary: We report a case of a middle-aged female who presented with severe COVID-19 disease with no neurological symptoms. She complained of diminished vision on day 7 of the illness and underwent an MRI brain to rule out an ischemic stroke but the findings were suggestive of PRES. She had no episode of hypertension during the hospital stay. Probably severe COVID-related inflammation was the reason for such a presentation. Conservative management resolved the issue and her symptoms weaned off. Conclusion: Severe COVID disease can lead to PRES-like symptoms and requires neuroimaging to validate it. Conservative management is the best treatment for such patients.


  • Open Access

    Post Total Thyroidectomy, Isolated Right Side Chylothorax with High Output Fistula Managed with Lymphangiography

    by Amit Goel, Deven Juneja, Omender Singh, Prashant Singh, Varun Arora, Dhruva Sharma

    Chylothorax is a rare complication after total thyroidectomy with radical neck dissection, and isolated right side chylothorax is even rarer. Treatment may be conservative or surgical. Besides being helpful in making a diagnosis, thoracic duct lymphangiography (TDL) may be therapeutic in some cases. However, its application in high output chylous leak is not fully explored. Here, we present a rare case of right-sided high output chylothorax, secondary to total thyroidectomy, successfully treated with TDL.

  • A novel treatment option for patients suffering from migraine: Erenumab

    by Neha Sharma, Dhruva Sharma, Uma Advani, Preksha Sharma, Ravi Prakash

    Migraine is one of the common disabling neurological disorders. It is conventionally treated by antihypertensives, antidepressants, and antiepileptics for prophylaxis. In spite of all these treatment options available, physicians were always in search of an ideal drug molecule with more target-specific drug action with lesser side effects and which may improve patient compliance. This exhaustive search led to the discovery of a new molecule in the pathophysiology of migraine that is calcitonin gene-related peptide (CGRP) and which in turn led to discovery of specific CGRP antagonists such as gepants and monoclonal antibodies such as erenumab. A systematic literature search was carried out on the internet using databases such as PubMed, Cochrane Reviews, Google Scholar, and Wikipedia using keywords such as migraine, erenumab, and CGRP receptor. Detailed information about pathophysiology of migraine, CGRP, and erenumab was gathered. Erenumab is the first human monoclonal antibody approved by the Food and Drug Administration in May 2018. It is marketed under the trade name “Aimovig.” It acts as an antagonist of CGRP receptors, which plays a key role in the pathophysiology of migraine. In spite of being macromolecular human monoclonal antibodies, it has very few side effects as compared to gepants. Erenumab may offer promising role in the preventive treatment of episodic and chronic migraine. The present study describes the mechanism of action, efficacy, and side effects as documented in three completed clinical trial findings of erenumab. The following core competencies are addressed in this article: Medical knowledge, Patient care and procedural skills.